The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.19, FiscalAI reports. The company had revenue of $26.86 million for the quarter, compared to analysts’ expectations of $26.03 million. Growth was supported by stronger adoption in both primary care and pulmonology, as well as improved average revenue per test. Growth was supported by stronger adoption in both primary care and pulmonology, as well as improved average revenue per test. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock.